Get the Daily Brief
Latest Biotech News
Harbour Biomed and Lannacheng tie up on radionuclide‑drug conjugates
Harbour Biomed and Yantai Lannacheng Biotechnology announced a strategic, long‑term collaboration to develop next‑generation radionuclide‑drug conjugates (RDCs) for cancer. The alliance combines...
Judge blocks 340B rebate pilot ahead of rollout — program paused
A federal judge in Maine issued an order blocking the implementation of the newest 340B rebate pilot program pending further action, temporarily halting a government effort aimed at changing drug...
Novo Nordisk prices Wegovy pill $299 — direct‑to‑consumer push undercuts Lilly
Novo Nordisk launched direct sales of its newly approved Wegovy oral formulation at $299 per month for cash‑pay customers, positioning the drug below pricing announced or expected from rivals. Eli...
2025 marks in‑vivo gene therapy breakthroughs — industry still hunting final editing tool
2025 delivered notable progress for in‑vivo gene therapies as developers reported improved delivery methods and encouraging preclinical and early clinical data, signaling momentum for one‑time...
Phase III bone drug fails – Ultragenyx and Mereo shares tumble
Two late-stage trials of setrusumab missed primary endpoints and triggered severe market reactions for their developers. Ultragenyx Pharmaceutical and Mereo Biopharma reported Phase III failures...
FDA clears Diasorin molecular point‑of‑care assay – 15‑minute four‑plex
The US Food and Drug Administration issued 510(k) clearance and CLIA waiver for Diasorin’s four‑plex molecular assay on the Liaison Nes platform, enabling point‑of‑care detection of influenza A/B,...
China approves Innovent’s ipilimumab–sintilimab neoadjuvant combo
China’s National Medical Products Administration approved Innovent Biologics’ Tabosun (ipilimumab N01, IBI‑310) in combination with sintilimab as neoadjuvant treatment for stage IIB–III resectable...
Boston‑area startup Nido Bio to wind down after Phase 2 miss
Nido Biosciences announced plans to wind down operations in early 2026 after Phase II clinical data fell short of expectations. The Boston‑area company had been testing a candidate in oncology,...
Genmab ends acasunlimab program after BioNTech exit
Genmab announced termination of clinical development for acasunlimab, a bispecific antibody that had been developed with BioNTech before the partner withdrew last year. Genmab said the decision...
Judge blocks 340B rebate pilot just before Jan. 1 rollout
A federal judge in Maine issued an order blocking implementation of the government's current iteration of the 340B rebate pilot program pending further order. The decision represents a legal...
Twice‑yearly depemokimab appears safe in asthma and nasal‑polyp studies
Clinical data released from trials of depemokimab, an IL‑5–targeting monoclonal antibody, report a favorable safety profile when dosed twice yearly for patients with asthma and chronic...
First‑in‑class GAS41 YEATS inhibitor surfaces for NSCLC
Researchers disclosed a first‑in‑class inhibitor targeting GAS41, the protein product of YEATS4, as a candidate for non‑small‑cell lung cancer where the target is frequently overexpressed....
Harbour Biomed and Lannacheng partner on radionuclide‑drug conjugates
Harbour Biomed announced a long‑term strategic collaboration with Yantai Lannacheng Biotechnology to advance next‑generation radionuclide‑drug conjugates for cancer therapy. The alliance combines...
Adlai Nortye licenses pan‑RAS inhibitor AN‑9025 to Ask Pharm
Adlai Nortye Ltd. granted Jiangsu Aosaikang Pharmaceutical (Ask Pharm) an exclusive license for AN‑9025, a pan‑RAS(ON) oral small molecule designed to target a broad spectrum of RAS mutations...
Phase III flop — setrusumab fails, Mereo and Ultragenyx hit hard
Two late‑stage clinical failures in brittle‑bone disease sent shockwaves through specialty biotech this week. Ultragenyx Pharmaceutical and Mereo Biopharma reported that Phase III trials of...
NMPA clears Innovent’s ipilimumab: neoadjuvant label for MSI‑H colon cancer
China’s National Medical Products Administration approved Innovent Biologics’ ipilimumab N01 (Tabosun, IBI‑310) in combination with sintilimab as neoadjuvant therapy for stage IIB–III resectable,...
FDA clears Diasorin molecular POC test — 15‑minute, CLIA‑waived four‑plex
The US Food and Drug Administration issued 510(k) clearance and a CLIA waiver for Diasorin’s LIAISON Nes molecular point‑of‑care platform and its four‑plex assay for influenza A/B, RSV and...
Genmab halts acasunlimab — program ends after BioNTech walk‑away
Genmab announced termination of clinical development for acasunlimab, a bispecific antibody that previously had been co‑developed with BioNTech before that partner exited the asset. The company...
Nido Bio to wind down after Phase II miss — Boston startup to shutter
Nido Biosciences announced it will wind down operations in early 2026 after Phase II data fell short of expectations, the company said in a LinkedIn post. The Boston‑area biotech, which had been...
Wegovy pill undercuts Lilly — Novo Nordisk lists direct price at $299
Novo Nordisk said it will sell the newly approved Wegovy oral formulation directly to patients at $299 per month for consumers paying out of pocket, undercutting pricing expectations for Eli...